Show simple item record

dc.rights.licenceAtribución-NoComercial 4.0 Internacional*
dc.contributor.authorGarzón Orjuela, Nathaly
dc.contributor.authorDer Werf, Laura van
dc.contributor.authorPrieto Pinto, Laura Catalina
dc.contributor.authorLasalvia, Pieralessandro
dc.contributor.authorCastañeda Cardona, Camilo
dc.contributor.authorRosselli, Diego
dc.date.accessioned2021-04-27T20:41:57Z
dc.date.available2021-04-27T20:41:57Z
dc.date.created2019
dc.identifierhttps://pubmed.ncbi.nlm.nih.gov/31890449/spa
dc.identifier.issn2186-3644spa
dc.identifier.urihttp://hdl.handle.net/10554/53732
dc.formatPDFspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.titleQuality of life in refractory generalized myasthenia gravis : a rapid review of the literaturespa
dc.type.hasversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.identifier.doihttps://doi.org/10.5582/irdr.2019.01121spa
dc.subject.keywordMyasthenia gravisspa
dc.subject.keywordRefractory generalized myasthenia gravisspa
dc.subject.keywordQuality of lifespa
dc.subject.keywordGeneralized myasthenia gravisspa
dc.description.abstractenglishGeneralized myasthenia gravis (GMG) is a neuromuscular transmission disorder that creates a fluctuating weakness of the voluntary muscles. This study is aimed at understanding the effect that refractory GMG has on the quality of life of patients who suffer from it, and the effect of eculizumab on it. A systematic literature search was conducted in MEDLINE (Ovid), EMBASE and the Cochrane Database of Systematic Reviews (Ovid). Eligibility criteria were verified via the title and summary and afterward through the full text. The risk of bias of the included randomized clinical trials was evaluated and the data were synthesized in a descriptive manner. Nine studies were identified that evaluated the quality of life of patients with GMG. Regarding the effect of eculizumab, two studies were identified. The quality of life in patients with GMG is lower compared to ocular myasthenia gravis (MG) and MG in remission, especially in the domains of physical function, physical role, bodily pain, vitality, and social function. Patients treated with eculizumab had a better perception of their quality of life compared to those who received placebo. GMG affects the quality of life more than other types of MG. This outcome is of great importance for the choice of therapeutic options in patients with refractory GMG. Eculizumab generates improvements in the perception of patients' quality of life compared to placebo, making it a relevant therapeutic option in the management of refractory GMG.spa
dc.type.localArtículosspa
dc.contributor.corporatenamePontificia Universidad Javeriana. Facultad de Medicina. Departamento de Epidemiología Clínica y Bioestadística
dc.identifier.instnameinstname:Pontificia Universidad Javerianaspa
dc.identifier.reponamereponame:Repositorio Institucional - Pontificia Universidad Javerianaspa
dc.identifier.repourlrepourl:https://repository.javeriana.edu.cospa
dc.type.coarhttp://purl.org/coar/resource_type/c_dcae04bcspa
dc.relation.citationstartpage231spa
dc.relation.citationendpage238spa
dc.relation.ispartofjournalIntractable and Rare Diseases Researchspa
dc.description.indexingN/Aspa
dc.relation.citationvolume8spa
dc.relation.citationissue4spa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial 4.0 Internacional
Except where otherwise noted, this item's license is described as Atribución-NoComercial 4.0 Internacional